Skip to main content
. Author manuscript; available in PMC: 2010 Nov 29.
Published in final edited form as: Transplantation. 2004 Oct 15;78(7):966–971. doi: 10.1097/01.tp.0000142674.78268.01

FIGURE 2.

FIGURE 2

(A) Course of alemtuzumab-pretreated recipient. Spaced weaning from tacrolimus monotherapy was started at 7.5 months and reduced progressively thereafter. After 15 months, treatment was stopped. (B) Interruption of weaning when rejection occurred after doses were reduced to 2 times/week. The patient was treated with three boluses of prednisone and temporarily returned to daily tacrolimus. Three months later, he was weaned to three doses per week and has been stable since.